Open an account

Neurosense Therapeutics

NRSN · NASDAQ

$2.39−$0.275 (−10.32%)TodayMarket closed ·
Prev close $2.67

NRSN analyst rating

BuyConsensus of 3 analysts over the last 12 months. 100% rate it a buy.
  • Strong buy0
  • Buy3
  • Hold0
  • Underperform0
  • Sell0

12-month price target · 6 analysts

Average $112.71 (+4615.9% upside)

Low
$52.52
Now
$2.39
High
$189.00

Upgrades and downgrades

The latest rating actions, newest first

NRSN analyst upgrades, downgrades and rating actions
FirmDateActionRating
HC Wainwright & Co.Sep 28, 2026MaintainsBuy
HC Wainwright & Co.Sep 3, 2026InitiatesBuy
D. Boral CapitalApr 8, 2026MaintainsBuy
D. Boral CapitalMar 25, 2026MaintainsBuy
D. Boral CapitalMar 17, 2026MaintainsBuy
Roth CapitalMar 10, 2026InitiatesBuy
D. Boral CapitalMar 9, 2026MaintainsBuy
D. Boral CapitalDec 22, 2025MaintainsBuy
D. Boral CapitalNov 24, 2025MaintainsBuy

The case for and against

Updated Oct 21, 2026

Bull case

NeuroSense Therapeutics is supported by PrimeC’s differentiated multi-target mechanism, which addresses shared neurodegenerative drivers such as neuroinflammation, autophagy dysfunction, miRNA imbalance, and iron dyshomeostasis rather than a single pathway. Phase 2b PARADIGM in ALS provided the strongest evidence, showing favorable tolerability, statistically significant TDP-43 reductions versus placebo, a 7.92-point ALSFRS-R advantage at month 18, and a 36.3-month median survival versus 21.4 months, while AD biomarker data from RoAD in 2Q26 further broaden the platform’s appeal. The outlook is tempered by financing risk, as the company ended 2025 with $0.17 million in cash and faces Nasdaq compliance issues, but the planned 4Q26 Canada filing and 1H27 PARAGON initiation create meaningful clinical and regulatory catalysts.

Bear case

NeuroSense Therapeutics is a highly speculative clinical-stage biotech whose value hinges almost entirely on PrimeC, while its limited cash position and the threat of dilutive financing or failed funding create immediate balance-sheet risk. Although PrimeC has shown encouraging ALS signals, including an 18% relative reduction in ALSFRS-R decline, a 30% relative reduction in FVC deterioration, and biomarker improvements in TDP-43, LC3, and miRNAs, these results remain from small, non-definitive studies and have not yet been validated in registrational trials. The company also faces listing and execution risk, with first-patient enrollment for the pivotal ALS trial still contingent on securing strategic resources and commercial adoption uncertain even if approval is achieved.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.